Development of a Cell Replacement Therapy Product for Insulin Dependent Diabetes
With a current prevalence of greater than 170 million individuals world-wide, diabetes has attained epidemic proportions. The widespread secondary complications this disease extract a relentless and costly toll on the patients and health care establishment required for their treatment. To date, cellular replacement therapies for the treatment of diabetes has been performed either by transplantation of whole pancreas, or via infusion of isolated primary pancreatic islets into the portal vein . While effective, the availability of such procedures is severely limited for the treatment of the general diabetes population since it relies upon the extremely limited supply of organs from deceased donors.
Disease Team Planning